Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer
Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 l...
Saved in:
| Published in | Cancer epidemiology, biomarkers & prevention Vol. 27; no. 12; pp. 1483 - 1490 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.12.2018
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 levels and affect specificity or sensitivity. We evaluated the association between common medical conditions and CA125 levels among women without ovarian cancer.
We used data and specimens from 2,004 women without ovarian cancer who participated in the New England Case Control study between 1992 and 2008. Participants completed in-person interviews and donated blood samples at enrollment. We measured CA125 using the CA125II assay and calculated the association between medical conditions and log-transformed CA125 using linear regression.
The median age of participants was 53 years and 1,119 (56%) were postmenopausal. The average CA125 level was 14.5 units/mL for premenopausal and 11.7 for postmenopausal women. Among premenopausal women, CA125 was significantly lower for women with colon polyps (
= 0.06) and hysterectomy (
= 0.01) and significantly higher with endometriosis (
= 0.05). CA125 was also significantly higher in premenopausal women with coronary artery disease (CVD) (
< 0.01,
= 2 cases) but not among postmenopausal with CVD (
= 79). Furthermore, among postmenopausal women, CA125 was significantly lower for women with osteoporosis, hypercholesterolemia, and osteoarthritis (
= 0.03, 0.02, and 0.01 respectively) and higher for women with a history of inflammatory bowel disease (
= 0.04).
Several chronic diseases are associated with CA125, which could influence the interpretation of CA125 in the context of ovarian cancer screening.
Consideration of chronic medical conditions may be necessary to interpret CA125 values. |
|---|---|
| AbstractList | Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 levels and affect specificity or sensitivity. We evaluated the association between common medical conditions and CA125 levels among women without ovarian cancer.BACKGROUNDRandomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 levels and affect specificity or sensitivity. We evaluated the association between common medical conditions and CA125 levels among women without ovarian cancer.We used data and specimens from 2,004 women without ovarian cancer who participated in the New England Case Control study between 1992 and 2008. Participants completed in-person interviews and donated blood samples at enrollment. We measured CA125 using the CA125II assay and calculated the association between medical conditions and log-transformed CA125 using linear regression.METHODSWe used data and specimens from 2,004 women without ovarian cancer who participated in the New England Case Control study between 1992 and 2008. Participants completed in-person interviews and donated blood samples at enrollment. We measured CA125 using the CA125II assay and calculated the association between medical conditions and log-transformed CA125 using linear regression.The median age of participants was 53 years and 1,119 (56%) were postmenopausal. The average CA125 level was 14.5 units/mL for premenopausal and 11.7 for postmenopausal women. Among premenopausal women, CA125 was significantly lower for women with colon polyps (P = 0.06) and hysterectomy (P = 0.01) and significantly higher with endometriosis (P = 0.05). CA125 was also significantly higher in premenopausal women with coronary artery disease (CVD) (P < 0.01, n = 2 cases) but not among postmenopausal with CVD (n = 79). Furthermore, among postmenopausal women, CA125 was significantly lower for women with osteoporosis, hypercholesterolemia, and osteoarthritis (P = 0.03, 0.02, and 0.01 respectively) and higher for women with a history of inflammatory bowel disease (P = 0.04).RESULTSThe median age of participants was 53 years and 1,119 (56%) were postmenopausal. The average CA125 level was 14.5 units/mL for premenopausal and 11.7 for postmenopausal women. Among premenopausal women, CA125 was significantly lower for women with colon polyps (P = 0.06) and hysterectomy (P = 0.01) and significantly higher with endometriosis (P = 0.05). CA125 was also significantly higher in premenopausal women with coronary artery disease (CVD) (P < 0.01, n = 2 cases) but not among postmenopausal with CVD (n = 79). Furthermore, among postmenopausal women, CA125 was significantly lower for women with osteoporosis, hypercholesterolemia, and osteoarthritis (P = 0.03, 0.02, and 0.01 respectively) and higher for women with a history of inflammatory bowel disease (P = 0.04).Several chronic diseases are associated with CA125, which could influence the interpretation of CA125 in the context of ovarian cancer screening.CONCLUSIONSSeveral chronic diseases are associated with CA125, which could influence the interpretation of CA125 in the context of ovarian cancer screening.Consideration of chronic medical conditions may be necessary to interpret CA125 values.IMPACTConsideration of chronic medical conditions may be necessary to interpret CA125 values. Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population screening for ovarian cancer. In part, this may be due to a lack of information about conditions, besides ovarian cancer, that can alter CA125 levels and affect specificity or sensitivity. We evaluated the association between common medical conditions and CA125 levels among women without ovarian cancer. We used data and specimens from 2,004 women without ovarian cancer who participated in the New England Case Control study between 1992 and 2008. Participants completed in-person interviews and donated blood samples at enrollment. We measured CA125 using the CA125II assay and calculated the association between medical conditions and log-transformed CA125 using linear regression. The median age of participants was 53 years and 1,119 (56%) were postmenopausal. The average CA125 level was 14.5 units/mL for premenopausal and 11.7 for postmenopausal women. Among premenopausal women, CA125 was significantly lower for women with colon polyps ( = 0.06) and hysterectomy ( = 0.01) and significantly higher with endometriosis ( = 0.05). CA125 was also significantly higher in premenopausal women with coronary artery disease (CVD) ( < 0.01, = 2 cases) but not among postmenopausal with CVD ( = 79). Furthermore, among postmenopausal women, CA125 was significantly lower for women with osteoporosis, hypercholesterolemia, and osteoarthritis ( = 0.03, 0.02, and 0.01 respectively) and higher for women with a history of inflammatory bowel disease ( = 0.04). Several chronic diseases are associated with CA125, which could influence the interpretation of CA125 in the context of ovarian cancer screening. Consideration of chronic medical conditions may be necessary to interpret CA125 values. |
| Author | Akinwunmi, Babatunde O. Titus, Linda Terry, Kathryn L. Babic, Ana Cramer, Daniel W. Vitonis, Allison F. Tworoger, Shelley S. |
| AuthorAffiliation | 6 Department of Global and Continuing Education, Harvard Medical School, Boston, Massachusetts 5 Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida 3 Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts 7 Departments of Epidemiology and Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, NH 2 Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 1 Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, Massachusetts 4 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts |
| AuthorAffiliation_xml | – name: 3 Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, Massachusetts – name: 6 Department of Global and Continuing Education, Harvard Medical School, Boston, Massachusetts – name: 7 Departments of Epidemiology and Pediatrics, Geisel School of Medicine at Dartmouth, Hanover, NH – name: 5 Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida – name: 2 Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts – name: 4 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts – name: 1 Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, Massachusetts |
| Author_xml | – sequence: 1 givenname: Babatunde O. surname: Akinwunmi fullname: Akinwunmi, Babatunde O. – sequence: 2 givenname: Ana surname: Babic fullname: Babic, Ana – sequence: 3 givenname: Allison F. surname: Vitonis fullname: Vitonis, Allison F. – sequence: 4 givenname: Daniel W. surname: Cramer fullname: Cramer, Daniel W. – sequence: 5 givenname: Linda surname: Titus fullname: Titus, Linda – sequence: 6 givenname: Shelley S. orcidid: 0000-0002-6986-7046 surname: Tworoger fullname: Tworoger, Shelley S. – sequence: 7 givenname: Kathryn L. surname: Terry fullname: Terry, Kathryn L. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30237250$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtv1DAUhS1URB_wE0BesknrR27sCAmpigqtNH0sQCytO47TMUrsYmem4t_jqA9BN3hjyz7nXOt8h2QvxOAIec_ZMeegTzgDqNq2geOzm4uK64oJJl-RAw5SV0oB7JXzk2afHOb8kzGmWoA3ZF8yIZUAdkCuuk2KwVt66XpvcaRdDL2ffQyZYuhpd8oF0JXbubFcTDHc0h9xcoHe-3kTtzO93mHyGGiHwbr0lrwecMzu3eN-RL5_OfvWnVer668X3emqsrVSc4UN101fCxRWSYSBaSvWIADW0mkrGeMWhsa2A9Zr3koUyIUSyHQz1ANnTB6Rzw-5d9v15HrrwpxwNHfJT5h-m4je_PsS_Mbcxp1pRKlAqhLw8TEgxV9bl2cz-WzdOGJwcZuN4GXVSktZpB_-nvU85KnEIoAHgU0x5-SGZwlnZoFlFhBmAWEKLMO1WWAV36cXPutnXLovX_bjf9x_AFTumUo |
| CitedBy_id | crossref_primary_10_3389_fendo_2022_963559 crossref_primary_10_3390_diagnostics13101703 crossref_primary_10_2147_DMSO_S250928 crossref_primary_10_2217_bmm_2023_0178 crossref_primary_10_3390_cancers17020262 crossref_primary_10_1016_j_bbcan_2021_188503 crossref_primary_10_1016_j_cancergen_2024_06_001 crossref_primary_10_1007_s12325_020_01363_5 crossref_primary_10_3390_life13081689 crossref_primary_10_3802_jgo_2024_35_e80 crossref_primary_10_18632_aging_103885 crossref_primary_10_2174_1386207326666230301141912 crossref_primary_10_1016_j_bbcan_2024_189188 crossref_primary_10_26508_lsa_202402658 crossref_primary_10_4103_abr_abr_100_23 crossref_primary_10_1186_s12885_023_11116_6 crossref_primary_10_1186_s13048_022_01066_1 crossref_primary_10_1186_s12885_022_09637_7 crossref_primary_10_3389_fonc_2024_1510988 crossref_primary_10_1177_22840265231178332 crossref_primary_10_3390_diagnostics14090949 crossref_primary_10_3390_cancers12123730 crossref_primary_10_1177_17588359241233225 crossref_primary_10_1016_j_jogoh_2020_101983 crossref_primary_10_1038_s41598_024_66509_9 crossref_primary_10_1158_1055_9965_EPI_23_1355 crossref_primary_10_3390_ijms23179981 crossref_primary_10_1016_j_matbio_2023_02_004 crossref_primary_10_1186_s13048_024_01487_0 crossref_primary_10_2147_IJWH_S444258 crossref_primary_10_1038_s41392_024_01823_2 crossref_primary_10_1177_22840265241275349 crossref_primary_10_2147_IJGM_S346610 crossref_primary_10_1016_j_gocm_2022_10_006 crossref_primary_10_1016_j_ygyno_2022_08_022 crossref_primary_10_1093_jb_mvae019 crossref_primary_10_3390_diagnostics12051212 crossref_primary_10_1038_s41598_024_71863_9 crossref_primary_10_3390_cells14050375 |
| Cites_doi | 10.1371/journal.pone.0126633 10.1111/j.1479-828X.2010.01183.x 10.1093/clinchem/37.11.1968 10.1097/MCA.0000000000000262 10.1177/172460089801300402 10.1006/gyno.2002.6708 10.1158/1940-6207.CAPR-10-0195 10.1371/journal.pone.0081328 10.20892/j.issn.2095-3941.2016.0084 10.1016/S0015-0282(16)55923-8 10.1200/JCO.2006.06.7884 10.1007/BF02850225 10.1093/jnci/djr344 10.1155/2014/981726 10.2174/1874306400903010123 10.3346/jkms.2011.26.10.1328 10.1093/annonc/mdr154 10.1007/s10552-016-0841-3 10.1007/s12253-014-9791-9 10.1016/j.ygyno.2008.05.006 10.1097/AOG.0b013e318212fcb7 10.1016/S0002-9149(96)00063-X 10.1111/j.1365-2362.2011.02592.x 10.1001/jama.2011.766 10.3322/caac.21442 10.1186/s13048-017-0315-6 10.1034/j.1600-0412.1998.770615.x 10.1016/j.amjcard.2012.05.030 10.1016/j.ejheart.2004.07.015 10.1002/jcla.20323 10.1016/j.ejheart.2008.04.012 10.5301/JBM.2012.9139 10.1016/j.humpath.2012.01.005 10.1016/S0140-6736(15)01224-6 10.1093/humrep/14.2.566 10.1007/s10741-011-9261-3 10.1253/jcj.57.489 10.1111/j.1365-2710.2008.00995.x 10.1111/j.1075-122X.2004.21374.x 10.1159/000217631 10.1177/1099800411412766 10.1093/rheumatology/37.11.1198 |
| ContentType | Journal Article |
| Copyright | 2018 American Association for Cancer Research. |
| Copyright_xml | – notice: 2018 American Association for Cancer Research. |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.1158/1055-9965.EPI-18-0203 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7755 |
| EndPage | 1490 |
| ExternalDocumentID | PMC6279537 30237250 10_1158_1055_9965_EPI_18_0203 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R01 CA193965 – fundername: NCI NIH HHS grantid: R01 CA054419 – fundername: NCI NIH HHS grantid: R35 CA197605 |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5VS 6J9 AAFWJ AAYXX ABOCM ACPRK ADBBV ADCOW AENEX AFHIN AFRAH ALMA_UNASSIGNED_HOLDINGS BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP H13 IH2 KQ8 L7B OK1 P2P PQQKQ QTD RCR RHI SJN W8F WOQ .55 3O- AI. C1A H~9 NPM UDS VH1 WHG X7M ZXP 7X8 5PM |
| ID | FETCH-LOGICAL-c477t-a6186d42a2c73a5f08c2b5255b3e8c3001c5f6c9fa4b193a2a1272a086f4f1003 |
| ISSN | 1055-9965 1538-7755 |
| IngestDate | Thu Aug 21 14:06:06 EDT 2025 Thu Jul 10 23:15:01 EDT 2025 Thu Apr 03 06:59:24 EDT 2025 Tue Jul 01 04:31:50 EDT 2025 Thu Apr 24 23:03:38 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | 2018 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c477t-a6186d42a2c73a5f08c2b5255b3e8c3001c5f6c9fa4b193a2a1272a086f4f1003 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| ORCID | 0000-0002-6986-7046 |
| OpenAccessLink | https://cebp.aacrjournals.org/content/cebp/27/12/1483.full.pdf |
| PMID | 30237250 |
| PQID | 2111147833 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6279537 proquest_miscellaneous_2111147833 pubmed_primary_30237250 crossref_primary_10_1158_1055_9965_EPI_18_0203 crossref_citationtrail_10_1158_1055_9965_EPI_18_0203 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-12-01 |
| PublicationDateYYYYMMDD | 2018-12-01 |
| PublicationDate_xml | – month: 12 year: 2018 text: 2018-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer epidemiology, biomarkers & prevention |
| PublicationTitleAlternate | Cancer Epidemiol Biomarkers Prev |
| PublicationYear | 2018 |
| References | Bon (2022060921064714100_bib36) 1999; 14 Rao (2022060921064714100_bib38) 2015; 10 Cecchi (2022060921064714100_bib33) 2009; 34 Whitehouse (2022060921064714100_bib5) 2003; 88 Fortner (2022060921064714100_bib13) 2017; 10 Pauler (2022060921064714100_bib14) 2001; 10 Siegel (2022060921064714100_bib1) 2018; 68 Rahimi-Rad (2022060921064714100_bib21) 2014; 63 Bast (2022060921064714100_bib6) 1998; 13 Dennison (2022060921064714100_bib48) 1998; 37 Babic (2022060921064714100_bib18) 2017; 28 Joo (2022060921064714100_bib31) 2011; 26 Kouris (2022060921064714100_bib19) 2005; 7 Johnson (2022060921064714100_bib8) 2008; 110 Hung (2022060921064714100_bib24) 2012; 110 De Gennaro (2022060921064714100_bib30) 2012; 42 Schmidt (2022060921064714100_bib39) 2011; 103 Singhal (2022060921064714100_bib22) 2012; 27 Hermsen (2022060921064714100_bib9) 2007; 25 Duman (2022060921064714100_bib15) 2008; 10 Omar (2022060921064714100_bib40) 1989; 10 Leonard (2022060921064714100_bib45) 2004; 10 Cheng (2022060921064714100_bib32) 2002; 99 Streppel (2022060921064714100_bib42) 2012; 43 Zeimet (2022060921064714100_bib10) 1993; 59 Reid (2022060921064714100_bib2) 2017; 14 Li (2022060921064714100_bib25) 2013; 8 Kłopocka (2022060921064714100_bib43) 2014; 2014 Grover (2022060921064714100_bib34) 1992; 79 Fortún (2022060921064714100_bib20) 2009; 3 Vitonis (2022060921064714100_bib23) 2011; 117 McLemore (2022060921064714100_bib35) 2012; 14 Zhong (2022060921064714100_bib41) 2015; 21 Seo (2022060921064714100_bib27) 1993; 57 Ataseven (2022060921064714100_bib37) 2009; 23 Buys (2022060921064714100_bib4) 2011; 305 Yalta (2022060921064714100_bib16) 2006; 23 Colombo (2022060921064714100_bib26) 2012; 17 Ahn (2022060921064714100_bib47) 2010; 50 MacGowan (2022060921064714100_bib28) 1997; 79 Westhoff (2022060921064714100_bib12) 1990; 76 Rauh-Hain (2022060921064714100_bib3) 2011; 4 Jacobs (2022060921064714100_bib7) 2016; 387 Chen (2022060921064714100_bib17) 1998; 77 Daoud (2022060921064714100_bib46) 1991; 37 Cramer (2022060921064714100_bib11) 2011; 4 Li (2022060921064714100_bib29) 2015; 26 Yerushalmi (2022060921064714100_bib44) 2012; 23 |
| References_xml | – volume: 10 start-page: e0126633 year: 2015 ident: 2022060921064714100_bib38 article-title: Expression of the carboxy-terminal portion of MUC16/CA125 induces transformation and tumor invasion publication-title: PLoS ONE doi: 10.1371/journal.pone.0126633 – volume: 50 start-page: 371 year: 2010 ident: 2022060921064714100_bib47 article-title: Relationship between the serum CA-125 level and bone mineral density in healthy pre- and post-menopausal women: CA-125 and bone mineral density publication-title: Aust N Z J Obstet Gynaecol doi: 10.1111/j.1479-828X.2010.01183.x – volume: 37 start-page: 1968 year: 1991 ident: 2022060921064714100_bib46 article-title: CA-125 concentrations in malignant and nonmalignant disease publication-title: Clin Chem doi: 10.1093/clinchem/37.11.1968 – volume: 26 start-page: 432 year: 2015 ident: 2022060921064714100_bib29 article-title: Carbohydrate antigen 125 levels and clinical outcomes after off-pump coronary artery bypass grafting publication-title: Coron Artery Dis doi: 10.1097/MCA.0000000000000262 – volume: 13 start-page: 179 year: 1998 ident: 2022060921064714100_bib6 article-title: CA 125: the past and the future publication-title: Int J Biol Markers doi: 10.1177/172460089801300402 – volume: 88 start-page: S152 year: 2003 ident: 2022060921064714100_bib5 article-title: Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening publication-title: Gynecol Oncol doi: 10.1006/gyno.2002.6708 – volume: 4 start-page: 365 year: 2011 ident: 2022060921064714100_bib11 article-title: Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens publication-title: Cancer Prev Res doi: 10.1158/1940-6207.CAPR-10-0195 – volume: 8 start-page: e81328 year: 2013 ident: 2022060921064714100_bib25 article-title: Higher carbohydrate antigen 125 levels are associated with increased risk of coronary heart disease in elderly chinese: a population-based case-control study publication-title: PLoS One doi: 10.1371/journal.pone.0081328 – volume: 14 start-page: 9 year: 2017 ident: 2022060921064714100_bib2 article-title: Epidemiology of ovarian cancer: a review publication-title: Cancer Biol Med doi: 10.20892/j.issn.2095-3941.2016.0084 – volume: 59 start-page: 1028 year: 1993 ident: 2022060921064714100_bib10 article-title: Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle publication-title: Fertil Steril doi: 10.1016/S0015-0282(16)55923-8 – volume: 25 start-page: 1383 year: 2007 ident: 2022060921064714100_bib9 article-title: Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.7884 – volume: 23 start-page: 1052 year: 2006 ident: 2022060921064714100_bib16 article-title: Evaluation of tumor markers CA-125 and CEA in acute myocardial infarction publication-title: Adv Ther doi: 10.1007/BF02850225 – volume: 103 start-page: 1290 year: 2011 ident: 2022060921064714100_bib39 article-title: CA-125: A biomarker put to the test publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djr344 – volume: 2014 start-page: 981726 year: 2014 ident: 2022060921064714100_bib43 article-title: Diagnostic difficulties in woman with Crohn's disease, ascites, and elevated value of serum CA125 antigen publication-title: Case Rep Med doi: 10.1155/2014/981726 – volume: 3 start-page: 123 year: 2009 ident: 2022060921064714100_bib20 article-title: CA-125: A useful marker to distinguish pulmonary tuberculosis from other pulmonary infections publication-title: Open Respir Med J doi: 10.2174/1874306400903010123 – volume: 26 start-page: 1328 year: 2011 ident: 2022060921064714100_bib31 article-title: Serum CA125 concentration has inverse correlation with metabolic syndrome publication-title: J Korean Med Sci doi: 10.3346/jkms.2011.26.10.1328 – volume: 79 start-page: 511 year: 1992 ident: 2022060921064714100_bib34 article-title: Factors influencing serum CA 125 levels in normal women publication-title: Obstet Gynecol – volume: 23 start-page: 338 year: 2012 ident: 2022060921064714100_bib44 article-title: Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome publication-title: Ann Oncol doi: 10.1093/annonc/mdr154 – volume: 63 start-page: 164 year: 2014 ident: 2022060921064714100_bib21 article-title: Serum CA-125 level in patients with chronic obstructive pulmonary disease with and without pulmonary hypertension publication-title: Pneumol Buchar Rom – volume: 28 start-page: 459 year: 2017 ident: 2022060921064714100_bib18 article-title: Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium publication-title: Cancer Causes Control doi: 10.1007/s10552-016-0841-3 – volume: 99 start-page: 375 year: 2002 ident: 2022060921064714100_bib32 article-title: Serum CA-125 in preoperative patients at high risk for endometriosis. publication-title: Obstet Gynecol – volume: 4 start-page: 15 year: 2011 ident: 2022060921064714100_bib3 article-title: Ovarian Cancer Screening and Early Detection in the General Population publication-title: Rev Obstet Gynecol – volume: 21 start-page: 83 year: 2015 ident: 2022060921064714100_bib41 article-title: Association of serum levels of CEA, CA199, CA125, CYFRA21–1 and CA72–4 and disease characteristics in colorectal cancer publication-title: Pathol Oncol Res doi: 10.1007/s12253-014-9791-9 – volume: 110 start-page: 383 year: 2008 ident: 2022060921064714100_bib8 article-title: The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial publication-title: Gynecol Oncol doi: 10.1016/j.ygyno.2008.05.006 – volume: 117 start-page: 1042 year: 2011 ident: 2022060921064714100_bib23 article-title: Assessing ovarian cancer risk when considering elective oophorectomy at the time of hysterectomy publication-title: Obstet Gynecol doi: 10.1097/AOG.0b013e318212fcb7 – volume: 79 start-page: 1128 year: 1997 ident: 2022060921064714100_bib28 article-title: Circulating interleukin-6 in severe heart failure publication-title: Am J Cardiol doi: 10.1016/S0002-9149(96)00063-X – volume: 42 start-page: 371 year: 2012 ident: 2022060921064714100_bib30 article-title: Inflammatory activation and carbohydrate antigen-125 levels in subjects with atrial fibrillation publication-title: Eur J Clin Invest doi: 10.1111/j.1365-2362.2011.02592.x – volume: 305 start-page: 2295 year: 2011 ident: 2022060921064714100_bib4 article-title: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial publication-title: JAMA doi: 10.1001/jama.2011.766 – volume: 68 start-page: 7 year: 2018 ident: 2022060921064714100_bib1 article-title: Cancer statistics, 2018 publication-title: CA Cancer J Clin doi: 10.3322/caac.21442 – volume: 10 start-page: 20 year: 2017 ident: 2022060921064714100_bib13 article-title: Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort publication-title: J Ovarian Res doi: 10.1186/s13048-017-0315-6 – volume: 77 start-page: 665 year: 1998 ident: 2022060921064714100_bib17 article-title: The use of serum CA-125 as a marker for endometriosis in patients with dysmenorrhea for monitoring therapy and for recurrence of endometriosis publication-title: Acta Obstet Gynecol Scand doi: 10.1034/j.1600-0412.1998.770615.x – volume: 110 start-page: 993 year: 2012 ident: 2022060921064714100_bib24 article-title: Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2012.05.030 – volume: 7 start-page: 199 year: 2005 ident: 2022060921064714100_bib19 article-title: The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. publication-title: Eur J Heart Fail doi: 10.1016/j.ejheart.2004.07.015 – volume: 76 start-page: 428 year: 1990 ident: 2022060921064714100_bib12 article-title: CA 125 levels in menopausal women publication-title: Obstet Gynecol – volume: 23 start-page: 244 year: 2009 ident: 2022060921064714100_bib37 article-title: Cancer antigen 125 levels in inflammatory bowel diseases publication-title: J Clin Lab Anal doi: 10.1002/jcla.20323 – volume: 10 start-page: 556 year: 2008 ident: 2022060921064714100_bib15 article-title: Serum carbohydrate antigen 125 levels in advanced heart failure: relation to B-type natriuretic peptide and left atrial volume publication-title: Eur J Heart Fail doi: 10.1016/j.ejheart.2008.04.012 – volume: 27 start-page: e147 year: 2012 ident: 2022060921064714100_bib22 article-title: Elevation of CA 125 and CA 19–9 in patients with end-stage liver disease publication-title: Int J Biol Markers doi: 10.5301/JBM.2012.9139 – volume: 43 start-page: 1755 year: 2012 ident: 2022060921064714100_bib42 article-title: Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon publication-title: Hum Pathol doi: 10.1016/j.humpath.2012.01.005 – volume: 387 start-page: 945 year: 2016 ident: 2022060921064714100_bib7 article-title: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial publication-title: The Lancet doi: 10.1016/S0140-6736(15)01224-6 – volume: 14 start-page: 566 year: 1999 ident: 2022060921064714100_bib36 article-title: Fluctuations in CA 125 and CA 15–3 serum concentrations during spontaneous ovulatory cycles publication-title: Hum Reprod doi: 10.1093/humrep/14.2.566 – volume: 17 start-page: 177 year: 2012 ident: 2022060921064714100_bib26 article-title: Inflammatory activation: cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome publication-title: Heart Fail Rev doi: 10.1007/s10741-011-9261-3 – volume: 10 start-page: 489 year: 2001 ident: 2022060921064714100_bib14 article-title: Factors influencing serum CA125II levels in healthy postmenopausal women publication-title: Cancer Epidemiol Biomark Prev – volume: 57 start-page: 489 year: 1993 ident: 2022060921064714100_bib27 article-title: Usefulness of serum CA125 measurement for monitoring pericardial effusion publication-title: Jpn Circ J doi: 10.1253/jcj.57.489 – volume: 34 start-page: 129 year: 2009 ident: 2022060921064714100_bib33 article-title: Increased levels of CA 125 and CA 19.9 serum tumour markers following cyclic combined hormone replacement therapy. publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2008.00995.x – volume: 10 start-page: 146 year: 2004 ident: 2022060921064714100_bib45 article-title: CA 125 elevation in breast cancer: a case report and review of the literature publication-title: Breast J doi: 10.1111/j.1075-122X.2004.21374.x – volume: 10 start-page: 316 year: 1989 ident: 2022060921064714100_bib40 article-title: Serum levels of CA 125 in patients with gastrointestinal cancers publication-title: Tumour Biol doi: 10.1159/000217631 – volume: 14 start-page: 250 year: 2012 ident: 2022060921064714100_bib35 article-title: A comparison of the cyclic variation in serum levels of CA125 across the menstrual cycle using two commercial assays publication-title: Biol Res Nurs doi: 10.1177/1099800411412766 – volume: 37 start-page: 1198 year: 1998 ident: 2022060921064714100_bib48 article-title: Hormone replacement therapy, other reproductive variables and symptomatic hip osteoarthritis in elderly white women: a case-control study publication-title: Br J Rheumatol doi: 10.1093/rheumatology/37.11.1198 |
| SSID | ssj0007955 |
| Score | 2.4584224 |
| Snippet | Randomized trials using the biomarker cancer antigen (CA) 125, with or without pelvic ultrasound, have failed to show a clear benefit of general population... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1483 |
| Title | Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30237250 https://www.proquest.com/docview/2111147833 https://pubmed.ncbi.nlm.nih.gov/PMC6279537 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zj9MwELbKIiFeEDflkpF4qxLa2I6dxyra1XLsLki7sG-RnTqioqSrHiDxr_iHzNhuki4VsLxEVRJPrM7n8YznIuQl4ECrrBSRtpmNODOTKKu4iRhPKp5qwzOLucNHx-nhGX9zLs57vZ-dqKX1ysTlj515Jf_DVbgHfMUs2StwtiEKN-A38BeuwGG4_hOPQ2XbxtuSz9EB7ULb8Dw8H4NeMXiHYUHL0FXINax0h68Yj3zyDSxlWOA5sn7R1VP9nYFt-8c6ZmCyPsbzLJYOMheh_lPryh9_mdbf1_XXqfdlGL3CJLXBSdyemJpp6SMpmw3hI0iVOrRFns1cT8SDZkCO0WOLNht-8CnunlSMVCfqwwvXoRAR2Ffei21bgSulL9W7kci-WsAGeUlHvoLxxjp7NZh3w937gFDuSCJ8MN5__zqCCaHbtd34Ns7-S_thE6Xo7COhCiRTIJkCyBQjVSCZa-R6ApYJita3H9oC9TJzjXabL4ekMSDzaudsttWh32ycy6G6Hd3n9Da5FYwWOvYIvEN6tr5LbhyFsIx75DgAkQYg0haIFIBIHRCpByJ1QKQOiDQAkQYgUg-7--TsYP80P4xCo46o5FKuIo1NFyaw6pNSMi2qoSoTI8BYNcyqkoEmVIoqLbNKcwMGg070KJGJBmu64tUI9pUHZK-e1_YRoalSxjDJJppzPsmEqqQSE8PE0DKb8axP-Ob_KspQxR6bqcyKP3KrT-Jm2IUv4_K3AS82zChA4KIXTdd2vl4WCSoZXCoG7zz0zGlIYgcuCUZFn8gttjUvYDH37Sf19LMr6p4mAB0mH191ok_IzXatPSV7q8XaPgM9eWWeO2T-AhSNtL0 |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chronic+Medical+Conditions+and+CA125+Levels+among+Women+without+Ovarian+Cancer&rft.jtitle=Cancer+epidemiology%2C+biomarkers+%26+prevention&rft.au=Akinwunmi%2C+Babatunde+O.&rft.au=Babic%2C+Ana&rft.au=Vitonis%2C+Allison+F.&rft.au=Cramer%2C+Daniel+W.&rft.date=2018-12-01&rft.issn=1055-9965&rft.eissn=1538-7755&rft.volume=27&rft.issue=12&rft.spage=1483&rft.epage=1490&rft_id=info:doi/10.1158%2F1055-9965.EPI-18-0203&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1055_9965_EPI_18_0203 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1055-9965&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1055-9965&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1055-9965&client=summon |